Alpitatug Biosimilar Monoclonal Antibody (Kallikrein 2) for Research

Cat No.: GMP-Bios-INN-1073

Anti-KLK2/KLK2A2/hGK-1/hK2 therapeutic antibody (Pre-made Alpitatug biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Alpitatug (development codes IMC-3C5/JNJ-69086420) is a humanized monoclonal antibody-drug conjugate targeting kallikrein-2 (KLK2), labeled with the alpha-emitting radioisotope actinium-225. It is developed by Janssen Research & Development for prostate cancer. It is in Phase I clinical development.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1073-1mg 1mg 3090
GMP-Bios-INN-1073-10mg 10mg
GMP-Bios-INN-1073-100mg 100mg
GMP-Bios-INN-1073-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Alpitatug biosimilar, Whole mAb, Anti-KLK2/KLK2A2/hGK-1/hK2 Antibody: Anti-Kallikrein 2/KLK2/Kallikrein-2/Glandular kallikrein-1 (hGK-1) therapeutic antibody
INN Name Alpitatug
Target KLK2/KLK2A2/hGK-1/hK2
Format Whole mAb
Derivation Humanized
Species Reactivity Human
CH1+2+3 Isotype G1
VD LC Kappa
Highest_Clin_Trial (Jan '20) TBC
Est. Status Active
100% SI Structure None
99% SI Structure None
95-98% SI Structure None
Year Proposed 2024
Year Recommended na
Companies TBC
Conditions Approved TBC
Conditions Active TBC
Conditions Discontinued TBC
Production na
Development Tech TBC